List of Excipients in Branded Drug CLINDAMYCIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	CLINDAMYCIN - BENZOYL PEROXIDE	clindamycin phosphate and benzoyl peroxide	66993-949	CARBOMER HOMOPOLYMER TYPE C
Prasco Laboratories	CLINDAMYCIN - BENZOYL PEROXIDE	clindamycin phosphate and benzoyl peroxide	66993-949	DIMETHICONE
Prasco Laboratories	CLINDAMYCIN - BENZOYL PEROXIDE	clindamycin phosphate and benzoyl peroxide	66993-949	DISODIUM LAURYL SULFOSUCCINATE

Generic Drugs Containing CLINDAMYCIN

Company	Ingredient	NDC	Excipient
Henry Schein Inc	clindamycin phosphate	0404-9838	BENZYL ALCOHOL
Henry Schein Inc	clindamycin phosphate	0404-9838	EDETATE DISODIUM
Henry Schein Inc	clindamycin phosphate	0404-9838	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in CLINDAMYCIN?

# Of NDCs	Excipient
15	BENZYL ALCOHOL
1	DEXTROSE MONOHYDRATE
16	EDETATE DISODIUM

Clindamycin Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Clindamycin is a mature generic antibiotic with limited active-ingredient exclusivity and substantial formulation differentiation potential. The strongest commercial opportunities are in pediatric taste masking, alcohol-free topical products, low-irritancy dermatology formulations, vaginal delivery systems, preservative-free injectables, and manufacturing platforms that improve stability and usability.

Clindamycin is marketed in several chemical forms:

• Clindamycin hydrochloride for oral capsules and oral solutions
• Clindamycin palmitate hydrochloride for oral suspension
• Clindamycin phosphate for injection, topical products, vaginal products, and some combination products

The molecule has broad generic availability. Commercial value is therefore driven by dosage form, patient adherence, tolerability, device design, supply reliability, and channel access rather than by compound patent protection.

What is the regulatory and commercial status of clindamycin?

Clindamycin is an established lincosamide antibiotic approved for serious bacterial infections and several topical and vaginal indications. FDA-approved products include oral capsules, oral granules for solution, injectable products, topical gels, lotions, solutions, foams, pledgets, and vaginal creams or suppositories.[1-5]

Product category	Active form	Main route	Commercial position
Oral capsules	Clindamycin hydrochloride	Oral	Generic, mature market
Oral solution or suspension	Clindamycin palmitate hydrochloride	Oral	Pediatric and adherence opportunity
Injection	Clindamycin phosphate	IV or IM	Hospital and institutional market
Topical solution, gel, lotion, foam	Clindamycin phosphate	Dermatologic	Acne market, highly competitive
Vaginal cream	Clindamycin phosphate	Intravaginal	Bacterial vaginosis market
Vaginal suppository	Clindamycin phosphate	Intravaginal	Alternative local-delivery product
Combination products	Usually clindamycin phosphate plus benzoyl peroxide or tretinoin	Topical	Branded and generic acne segment

Clindamycin carries a prominent warning for potentially severe and fatal Clostridioides difficile-associated diarrhea and colitis. The warning applies across systemic products and affects prescribing, labeling, antimicrobial stewardship, and commercial positioning.[1,2]

When does clindamycin lose exclusivity?

Clindamycin’s original compound and early product protections expired decades ago. The commercial market is primarily generic, with no meaningful system-wide new chemical entity exclusivity remaining.

Product-specific patents can still arise around:

• Topical vehicles
• Combination products
• Controlled-release systems
• Applicators and delivery devices
• Manufacturing processes
• Particle-size control
• Polymers and bioadhesive compositions
• Specific treatment regimens

These rights do not recreate compound-level exclusivity. They can delay or narrow competition for a particular formulation, but the underlying active ingredient remains widely available.

What is the Orange Book status of clindamycin?

The FDA Orange Book contains product-specific listings for approved clindamycin products and certain branded or combination formulations. Orange Book exposure must be assessed by product and application number because a formulation patent listed against one clindamycin product does not automatically cover other dosage forms.[6]

A launch assessment should distinguish:

1. Clindamycin hydrochloride capsules
2. Clindamycin palmitate oral suspension
3. Clindamycin phosphate injection
4. Topical clindamycin monotherapy
5. Clindamycin-benzoyl peroxide combinations
6. Vaginal clindamycin products

The major entry risk for a new generic is usually regulatory equivalence, formulation performance, device compatibility, and market access rather than a surviving core molecule patent.

How many patents cover clindamycin formulations?

There is no single useful patent count for clindamycin. Patent families differ by chemical form, route, jurisdiction, assignee, and whether the rights remain enforceable.

The meaningful patent categories are:

Patent category	Typical subject matter	Relevance
Composition patents	Clindamycin with benzoyl peroxide, retinoids, antifungals, or other actives	High for combination products
Vehicle patents	Gels, emulsions, foams, lotions, suspensions	Moderate to high for branded dermatology
Delivery patents	Vaginal applicators, bioadhesive systems, sustained release	Moderate
Process patents	Crystallization, purification, particle engineering, sterile manufacture	Moderate
Method-of-use patents	Acne, bacterial vaginosis, specific dosing regimens	Product-specific
Device patents	Metered pumps, prefilled applicators, single-dose systems	Commercially relevant

A freedom-to-operate analysis should search active US, European, and key Asian families by chemical form and dosage form. Patent status should be verified in the USPTO Patent Center, EPO Espacenet, WIPO Patentscope, and the FDA Orange Book before investment or launch decisions.

What excipients are used in clindamycin products?

Excipient selection is route-specific because clindamycin products face different stability, tolerability, sterility, and patient-use requirements.

Oral capsules

Clindamycin hydrochloride capsules typically use hard gelatin shells, lactose or other fillers, starch-based disintegrants, magnesium stearate, talc, and colorants. Exact formulas vary by manufacturer.[1]

Key development issues include:

• Capsule size and swallowing burden
• Moisture protection
• Compatibility with gelatin or vegetarian capsule shells
• Dose proportionality across strengths
• Robust dissolution after storage
• Reduction of gastrointestinal irritation through administration instructions

The opportunity is not usually a radically new capsule. It is a lower-cost, globally scalable capsule platform with reliable dissolution, fewer allergens, and efficient packaging.

Oral liquid and pediatric suspension

Clindamycin palmitate hydrochloride is used for oral solutions or suspensions because it improves pediatric administration relative to solid capsules. Typical formulations use purified water after reconstitution, sweeteners, flavors, suspending agents, buffers, and preservatives.[2]

The most valuable excipient problems are:

• Extremely bitter taste
• Aftertaste and mouthfeel
• Sedimentation and redispersibility
• Short in-use stability after reconstitution
• Pediatric preservative exposure
• Dosing accuracy with household spoons
• Limited cold-chain practicality in some markets

Potential excipient strategies include:

• Ion-exchange resins for taste masking
• Polymer coating of drug particles
• Microencapsulation
• High-efficiency flavor systems
• Reduced-sugar or sugar-free vehicles
• Xylitol, sorbitol, or other alternative sweetener systems
• Suspending agents with rapid redispersion
• Unit-dose sachets or ready-to-use bottles
• Oral syringes calibrated to the prescribed dose

Taste masking has a direct commercial rationale. Pediatric antibiotic adherence is sensitive to bitterness, and caregivers often discontinue or underdose medicines that children reject. A formulation with equivalent active exposure and materially improved palatability can support hospital formulary adoption and private-label partnerships.

What topical formulations are protected by clindamycin patents?

Topical clindamycin products are differentiated mainly through the vehicle rather than the active ingredient. Products include aqueous solutions, hydroalcoholic gels, lotions, foams, and combination formulations.[3,4]

Topical excipient priorities

A topical clindamycin platform should evaluate:

• Alcohol concentration
• Drying time
• Skin feel
• Residue and pilling
• Occlusivity
• Fragrance and odor
• Preservative system
• pH
• Compatibility with acne regimens
• Irritation and sensitization
• Packaging loss in pumps or tubes

Alcohol-containing vehicles can improve drying and reduce microbial risk, but they may increase stinging, dryness, and irritation. Alcohol-free gels, emulsions, and low-residue foams offer a clear differentiation path for patients with sensitive or barrier-impaired skin.

Acne combination products

Clindamycin is often combined with benzoyl peroxide to reduce the risk of antibiotic resistance and improve acne treatment performance. The principal formulation challenges are chemical stability, discoloration, peroxide compatibility, and package protection.[4]

Commercial opportunities include:

• Dual-chamber packaging
• Separate-component systems mixed at use
• Airless pumps
• Light- and oxygen-protective containers
• Lower-irritancy vehicles
• Fragrance-free and non-comedogenic formulations
• Fixed-dose products with simplified dosing

Combination-product patents can be more commercially relevant than patents covering clindamycin alone. A generic or follow-on developer must evaluate whether the product is approved as a conventional ANDA, a 505(b)(2) application, or another pathway based on the reference product and formulation changes.

What vaginal formulations are protected by clindamycin patents?

Clindamycin phosphate vaginal products include cream and suppository dosage forms. Commercial differentiation focuses on residence time, leakage, applicator design, preservative exposure, and patient convenience.[5]

Vaginal excipient strategy

Useful development objectives include:

• Reduced leakage after administration
• Improved mucosal residence
• Lower applicator waste
• Less mess during overnight use
• Single-dose or shorter-course regimens where clinically supported
• Compatibility with latex and non-latex barrier products
• Reduced irritation
• Robust microbial control without excessive preservative burden

Creams commonly use semisolid bases, emulsifiers, preservatives, and stabilizers. Suppositories use a fatty or synthetic base designed to melt or disperse at body temperature.

Bioadhesive polymers, thermogelling systems, and mucoadhesive tablets can create differentiated products, but they also introduce regulatory complexity. Changes in local exposure, retention, tissue tolerability, and microbiological performance may require more than routine pharmaceutical equivalence testing.

What excipients are used in injectable clindamycin?

Clindamycin phosphate injection is a sterile parenteral product used intravenously or intramuscularly. Labeling identifies excipients such as benzyl alcohol, disodium edetate, and water for injection in certain products, although compositions vary by manufacturer.[1]

Injectable formulation risks

The main excipient and container risks include:

• Benzyl alcohol exposure, particularly in neonates and vulnerable pediatric patients
• Precipitation after dilution
• Compatibility with infusion solutions
• Adsorption to tubing or containers
• pH-related degradation
• Particulate formation
• Container-closure interaction
• Sterilization and aseptic-processing burden

A commercially attractive hospital product could be a preservative-free, ready-to-use presentation in a compatible infusion bag or syringe. Such a product would target pharmacy compounding reduction, lower preparation error, and faster administration.

The regulatory burden is higher than for a conventional generic vial. Container compatibility, extractables and leachables, stability after dilution, sterility assurance, and administration-device validation become central development requirements.

What generic entry risks exist for clindamycin?

Generic entry risk is high for conventional clindamycin capsules and injection products because the market is mature and multiple suppliers exist. Risk is more variable for specialty formulations.

Product type	Generic entry risk	Main barrier
Capsules	High	Price competition and limited differentiation
Oral suspension	Medium	Taste, stability, and pediatric usability
Standard injection vial	High	Manufacturing scale and hospital contracting
Ready-to-use injection	Medium	Sterility, packaging, and compatibility
Topical solution	High	Simple formulation and crowded market
Topical foam	Medium	Device, propellant, and vehicle complexity
Acne combination	Medium	Stability and formulation patents
Vaginal cream	Medium	Applicator, local equivalence, and vehicle
Vaginal bioadhesive system	Lower initially	Clinical, local-tolerance, and CMC requirements

Which companies are challenging clindamycin products?

Competition is fragmented across generic manufacturers, specialty dermatology companies, contract development and manufacturing organizations, and branded combination-product developers. The market commonly includes large generic suppliers such as Teva, Viatris, Sandoz, Perrigo, Hikma, and related regional manufacturers, together with smaller dermatology-focused companies.

A precise list of current Paragraph IV challengers requires product-specific review of FDA ANDA litigation records and Orange Book listings. Clindamycin’s mature core products generally face abbreviated applications and ordinary generic competition rather than a concentrated, high-value Paragraph IV campaign.

What FDA regulatory pathway applies to new clindamycin formulations?

The pathway depends on how much the proposed product differs from the reference product.

ANDA pathway

An ANDA is generally appropriate when the product matches the reference in active ingredient, dosage form, strength, route, and relevant performance characteristics. Conventional capsules, solutions, suspensions, injections, topical products, and vaginal products may qualify if the formulation and equivalence requirements are met.

505(b)(2) pathway

A 505(b)(2) application may be more suitable for:

• New delivery systems
• Modified-release products
• New concentrations
• New excipient systems with meaningful formulation changes
• New applicators
• Ready-to-use parenteral presentations
• Alternative dosage forms
• Products relying partly on published literature or prior FDA findings

A 505(b)(2) strategy can create limited regulatory exclusivity, but it does not necessarily provide broad commercial protection. The value depends on whether the product solves a high-cost clinical or operational problem.

How strong is the clindamycin patent estate?

The core clindamycin patent estate is weak because the molecule is old and generic. Formulation and combination-product estates can be stronger but are narrow and highly dependent on claim scope, prosecution history, and jurisdiction.

Estate layer	Relative strength	Business implication
Core molecule	Low	Does not block ordinary generic entry
Conventional capsule	Low	Commodity economics
Pediatric taste-masked liquid	Medium	Potential differentiation if claims cover composition and performance
Topical vehicle	Medium	May support branded or specialty positioning
Combination acne product	Medium to high	Stability and composition claims can matter
Vaginal delivery system	Medium	Device and local-delivery claims may create barriers
Ready-to-use injection	Medium	Manufacturing and container claims may support defensibility
Manufacturing process	Variable	Strong only when difficult to design around or scale

A defensible formulation estate should combine composition claims with process, packaging, device, and use claims. A single broad excipient claim is less reliable than a layered portfolio covering the formulation and its commercial presentation.

What licensing deals and commercial partnerships are available?

Clindamycin is more likely to support supply, licensing, and private-label agreements than large strategic acquisitions. Relevant partnership models include:

• API supply agreements
• Contract manufacturing of sterile injectables
• Private-label pediatric liquids
• Dermatology co-development
• Hospital distribution partnerships
• Regional licensing for topical or vaginal products
• Device partnerships for metered pumps and applicators
• Co-packaging and pharmacy-compounding substitution programs

The most attractive licensing assets are not basic clindamycin capsules. They are differentiated products with established manufacturing, stable supply, validated packaging, and a regulatory filing that can be transferred across territories.

How does clindamycin compare with competing antibiotics?

Clindamycin competes with beta-lactams, macrolides, tetracyclines, metronidazole, and other agents depending on infection and route.

Attribute	Clindamycin	Common commercial implication
Oral administration	Available, but gastrointestinal tolerability is important	Taste and adherence matter
Topical acne use	Established	Vehicle differentiation is essential
Vaginal use	Established	Local delivery and convenience drive value
Injectable use	Established	Ready-to-use formats can reduce hospital labor
Resistance concern	Important	Combination acne products have stronger stewardship rationale
C. difficile risk	Prominent	Restricts systemic overuse and affects positioning
API maturity	High	Low raw-material differentiation
Formulation opportunity	Moderate to high	Best in specialty dosage forms

Doxycycline and minocycline are major acne competitors. Metronidazole and other anti-infectives compete in bacterial vaginosis. For hospital use, clindamycin competes with other agents selected according to pathogen susceptibility, allergy status, infection site, and stewardship policy.

What commercial opportunities have the highest value?

1. Pediatric palatable oral suspension

This is the clearest patient-centered opportunity. A product with strong taste masking, accurate dosing, rapid redispersion, and stable shelf life can command better formulary consideration than a standard liquid.

2. Alcohol-free topical clindamycin

A low-irritancy, non-sticky, alcohol-free product could target patients who discontinue hydroalcoholic products because of burning or dryness.

3. Ready-to-use hospital injection

A premixed bag, syringe, or pharmacy-ready presentation could reduce preparation time and compounding errors. The opportunity depends on demonstrating adequate stability and compatibility.

4. Improved vaginal delivery

A low-leakage, lower-mess, patient-friendly system could differentiate clindamycin vaginal therapy. Applicator ergonomics and packaging can be as important as the excipient base.

5. Combination acne products

Clindamycin with benzoyl peroxide remains commercially relevant where the formulation is stable, cosmetically acceptable, and aligned with antimicrobial stewardship. The strongest value proposition is a convenient fixed-dose product with low irritation and reliable peroxide protection.

What manufacturing and intellectual-property barriers matter?

The principal manufacturing barriers are formulation reproducibility, sterile processing, packaging compatibility, and scale-up.

Key risks include:

• Particle-size variability in suspensions
• Taste-mask coating uniformity
• Peroxide-driven degradation
• Polymer or emulsion instability
• Sterile filtration and aseptic filling
• Extractables from plastic containers
• Pump-dose uniformity
• Vaginal applicator fill accuracy
• API impurity control
• Regional excipient restrictions

Geographic coverage matters because excipient permissions, preservative limits, labeling requirements, and reference-product standards vary across the United States, European Union, Japan, China, India, and emerging markets.

What patent litigation and settlement issues affect clindamycin?

Litigation risk is concentrated in branded topical and combination products rather than old standalone clindamycin dosage forms. Potential disputes can involve:

• Orange Book-listed formulation patents
• Paragraph IV certifications
• Non-infringement and invalidity claims
• Patent-term calculations
• Skinny-label method-of-use carve-outs
• Device or packaging patents
• Formulation patents covering a specific excipient ratio

Settlement agreements may include delayed generic launch dates, licensing terms, authorized-generic provisions, or manufacturing restrictions. Each product must be reviewed separately because litigation outcomes for one clindamycin formulation do not establish freedom to launch another.

Key Takeaways

• Clindamycin is a mature generic antibiotic with little or no practical compound-level exclusivity.
• The strongest commercial opportunities are formulation-led.
• Pediatric taste masking is the most direct adherence opportunity.
• Alcohol-free topical products can differentiate through tolerability and cosmetic performance.
• Ready-to-use injectable presentations can target hospital labor and medication-preparation costs.
• Vaginal delivery systems can compete through residence time, reduced leakage, and applicator design.
• Acne combination products require careful attention to benzoyl peroxide stability, packaging, and formulation patents.
• Patent value is concentrated in vehicles, combinations, devices, manufacturing processes, and method-of-use claims.
• Conventional capsules and standard injection vials face high generic-entry and price-competition risk.
• A layered IP portfolio covering composition, process, packaging, and device design is stronger than a single excipient claim.

FAQs

Can clindamycin be reformulated with fewer preservatives?

Yes. Preservative reduction or elimination is most practical in single-use, sterile, anhydrous, or barrier-packaged products. Multidose oral and topical products require validated microbial-control strategies.

What is the best excipient approach for clindamycin bitterness?

Ion-exchange resins, polymer-coated particles, microencapsulation, and optimized sweetener-flavor systems are the principal approaches. The formulation must preserve dose uniformity, dissolution, and pediatric acceptability.

Can a clindamycin topical product be developed without alcohol?

Yes. Alcohol-free gels, emulsions, lotions, and foams are feasible. The development trade-off involves drying time, preservative performance, skin feel, drug release, and microbial robustness.

Is clindamycin suitable for a long-acting delivery system?

Potentially, but long-acting products would require substantial development work on local tolerability, release kinetics, tissue exposure, and regulatory bridging. The commercial rationale is stronger for local vaginal or topical delivery than for systemic administration.

Which clindamycin product has the greatest licensing potential?

A differentiated pediatric suspension, specialty topical combination, or ready-to-use injectable presentation generally offers more licensing value than a conventional capsule. The asset must include regulatory progress, scalable manufacturing, stable supply, and defensible formulation or device rights.

References

1. U.S. Food and Drug Administration. (2023). Clindamycin hydrochloride capsules prescribing information. FDA/DailyMed.
2. U.S. Food and Drug Administration. (2023). Clindamycin palmitate hydrochloride oral solution prescribing information. FDA/DailyMed.
3. U.S. Food and Drug Administration. (2023). Clindamycin phosphate topical gel prescribing information. FDA/DailyMed.
4. U.S. Food and Drug Administration. (2023). Clindamycin phosphate and benzoyl peroxide topical gel prescribing information. FDA/DailyMed.
5. U.S. Food and Drug Administration. (2023). Clindamycin phosphate vaginal cream prescribing information. FDA/DailyMed.
6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
7. U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations: Patent and exclusivity information. FDA Orange Book.
8. U.S. Food and Drug Administration. (2022). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA guidance.